WallStreetZenWallStreetZen

NYSEMKT: LCTX
Lineage Cell Therapeutics Inc Stock Ownership - Who owns Lineage Cell Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Lineage Cell Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Brian M. CulleyPresident and CEO2025-12-19334$1.68
$561.12Sell
George A. Samuel IiiGeneral Counsel and Secretary2025-12-1965$1.68
$109.20Sell
Brian M. CulleyPresident and CEO2025-02-1112,547$0.65
$8.16kSell
George A. Samuel IiiGeneral Counsel2025-02-112,440$0.65
$1.59kSell
Broadwood Partners LPDirector2025-01-277,894,737$0.76
$6.00MBuy

1 of 1

LCTX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when LCTX insiders and whales buy or sell their stock.

LCTX Shareholders

What type of owners hold Lineage Cell Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Broadwood Partners LP35.40%81,531,259$133.71MInsider
Broadwood Capital Inc21.52%49,560,992$81.28MInstitution
Neal C. Bradsher20.63%47,515,269$77.93MInsider
Alfred D. Kingsley4.49%10,344,637$16.97MInsider
Vanguard Group Inc3.91%9,006,930$14.77MInstitution
Raffles Associates LP2.34%5,387,788$8.84MInstitution
George Karfunkel2.16%4,982,217$8.17MInsider
Comerica Bank2.00%4,600,000$7.54MInstitution
Millennium Management LLC1.16%2,680,003$4.40MInstitution
Gary K. Duberstein1.12%2,590,408$4.25MInsider

1 of 3

LCTX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
LCTX36.54%63.46%Net BuyingNet Selling
RCKT50.65%49.35%Net SellingNet Selling
PRTC0.04%0.00%
AKBA46.61%7.64%Net Selling
TRDA45.50%54.50%Net SellingNet Selling
View Top Biotech Stocks

Lineage Cell Therapeutics Stock Ownership FAQ

Who owns Lineage Cell Therapeutics?

Lineage Cell Therapeutics (NYSEMKT: LCTX) is owned by 38.17% institutional shareholders, 66.29% Lineage Cell Therapeutics insiders, and 0.00% retail investors. Broadwood Partners LP is the largest individual Lineage Cell Therapeutics shareholder, owning 81.53M shares representing 35.40% of the company. Broadwood Partners LP's Lineage Cell Therapeutics shares are currently valued at $137.79M.

If you're new to stock investing, here's how to buy Lineage Cell Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.